Why the study?
Do renin inhibitors lower blood pressure in preclinical models?
Do renin inhibitors lower blood pressure in preclinical models?
Renin inhibitors demonstrate potent blood pressure-lowering effects in primate models comparable to ACE inhibitors, though oral bioavailability remains a challenge.
Answers are grounded in this paper and cite their sources.
Supports BP-lowering potential of renin inhibitors in primates; leaves open clinical development pending improved oral bioavailability.
Renin inhibitors represent an alternative to angiotensin-converting enzyme inhibitors (ACEI) for the treatment of hypertension. They inhibit the renin-angiotensin system at its first and rate limiting step, the renin-angiotensinogen reaction. Passive administration of angiotensinogen or renin antibodies lowers blood pressure in primates to the same extent as ACEI. Chronic active immunization against renin decreases blood pressure markedly in normotensive marmosets. Renin can be inhibited by peptides derived from its prosegment. The design of compounds based on pepstatin and on angiotensinogen sequence has led to very potent and specific human renin inhibitors. Such inhibitors are active by the IV route in primates but still lack of good oral activity.
No takes yet. Share an insight, caveat, or question.
Corvol et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: